PMID- 34489872
OWN - NLM
STAT- MEDLINE
DCOM- 20220214
LR  - 20220214
IS  - 1664-2392 (Print)
IS  - 1664-2392 (Electronic)
IS  - 1664-2392 (Linking)
VI  - 12
DP  - 2021
TI  - Roles and Mechanisms of Dipeptidyl Peptidase 4 Inhibitors in Vascular Aging.
PG  - 731273
LID - 10.3389/fendo.2021.731273 [doi]
LID - 731273
AB  - Vascular aging is characterized by alterations in the constitutive properties and 
      biological functions of the blood vessel wall. Endothelial cells (ECs) and 
      vascular smooth muscle cells (VSMCs) are indispensability elements in the inner 
      layer and the medial layer of the blood vessel wall, respectively. Dipeptidyl 
      peptidase-4 (DPP4) inhibitors, as a hypoglycemic agent, play a protective role in 
      reversing vascular aging regardless of their effects in meliorating glycemic 
      control in humans and animal models of type 2 diabetes mellitus (T2DM) through 
      complex cellular mechanisms, including improving EC dysfunction, promoting EC 
      proliferation and migration, alleviating EC senescence, obstructing EC apoptosis, 
      suppressing the proliferation and migration of VSMCs, increasing circulating 
      endothelial progenitor cell (EPC) levels, and preventing the infiltration of 
      mononuclear macrophages. All of these showed that DPP4 inhibitors may exert a 
      positive effect against vascular aging, thereby preventing vascular aging-related 
      diseases. In the current review, we will summarize the cellular mechanism of DPP4 
      inhibitors regulating vascular aging; moreover, we also intend to compile the 
      roles and the promising therapeutic application of DPP4 inhibitors in vascular 
      aging-related diseases.
CI  - Copyright (c) 2021 Cao, Wu, Zhu and Bao.
FAU - Cao, Fen
AU  - Cao F
AD  - Department of Cardiology, Huaihua First People's Hospital, Huaihua, China.
FAU - Wu, Kun
AU  - Wu K
AD  - Department of Neurology, Huaihua First People's Hospital, Huaihua, China.
FAU - Zhu, Yong-Zhi
AU  - Zhu YZ
AD  - Department of Cardiology, Huaihua First People's Hospital, Huaihua, China.
FAU - Bao, Zhong-Wu
AU  - Bao ZW
AD  - Department of Cardiology, Huaihua First People's Hospital, Huaihua, China.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20210817
PL  - Switzerland
TA  - Front Endocrinol (Lausanne)
JT  - Frontiers in endocrinology
JID - 101555782
RN  - 0 (Dipeptidyl-Peptidase IV Inhibitors)
SB  - IM
MH  - Aging/drug effects/*pathology
MH  - Animals
MH  - Diabetes Mellitus, Type 2/complications/drug therapy/pathology/physiopathology
MH  - Diabetic Angiopathies/etiology/pathology/physiopathology/prevention & control
MH  - Dipeptidyl-Peptidase IV Inhibitors/*pharmacology/therapeutic use
MH  - Endothelial Cells/drug effects/pathology/physiology
MH  - Humans
MH  - Signal Transduction/drug effects
MH  - Vascular Diseases/*drug therapy/*etiology
PMC - PMC8416540
OTO - NOTNLM
OT  - DPP4 inhibitors
OT  - diseases
OT  - endothelial cells
OT  - endothelial progenitor cells
OT  - mononuclear macrophages
OT  - vascular aging
OT  - vascular smooth muscle cells
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2021/09/08 06:00
MHDA- 2022/02/15 06:00
PMCR- 2021/01/01
CRDT- 2021/09/07 07:43
PHST- 2021/06/26 00:00 [received]
PHST- 2021/07/21 00:00 [accepted]
PHST- 2021/09/07 07:43 [entrez]
PHST- 2021/09/08 06:00 [pubmed]
PHST- 2022/02/15 06:00 [medline]
PHST- 2021/01/01 00:00 [pmc-release]
AID - 10.3389/fendo.2021.731273 [doi]
PST - epublish
SO  - Front Endocrinol (Lausanne). 2021 Aug 17;12:731273. doi: 
      10.3389/fendo.2021.731273. eCollection 2021.